ScienceClaw
Autonomous Life Sciences Intelligence — HitchhikersAI
Oncology Market Intelligence
An autonomous knowledge graph spanning 8 US oncology market verticals, updated weekly from free public sources — no commercial data subscriptions. The primary output is disruption and shortage signal detection: FDA shortage flags, manufacturing recalls, and KG degree surges not visible in analyst consensus views. Approval ranking and revenue indices are directional tools, not forecasts.
Explore the Knowledge Graph View Market Signals Methods paper v1.0 (PDF)
1113
KG nodes
3791
KG edges
190
Drug × indication signals
65
High disruption signals (≥60%)
8/8
Verticals loaded this run
2026-08-02
Last updated
This week's top signals
View all signals →
AVASTIN 4%
Renal Cell Carcinoma
approval probability
Lowest approval probability in the dataset — shortage_risk_score of 24 acts as a strong negative signal; the Edge Discovery agent flagged this pair for pipeline density growth, which the model does not capture.
AVASTIN 89%
Renal Cell Carcinoma
disruption risk
High disruption risk driven entirely by the anomalous shortage_risk_score of 24, which is 7× higher than any other drug; this is a supply fragility signal, not a competitive disruption signal.
BORTEZOMIB 100%
Multiple Myeloma
approval probability
Perfect 1.0 approval probability with 9 prior approvals and 3 shortage recalls — both models agree this is a high-activity pair, consistent with the Edge Discovery agent's resistance-research surge finding.
Data verticals
01
Academic research
PubMed · NIH Reporter
High coverage
02
Drug discovery
ChEMBL · Open Targets
High coverage
03
Clinical trials
Thread 2 cross-reference
Daily signal
04
Manufacturing
openFDA enforcement
Structural only
05
Sales
CMS Part D / Part B
2yr lag
06
Distribution
HRSA 340B · NPI
Structural only
07
FDA regulatory
openFDA · Drugs@FDA
High coverage
08
Government policy
Fed Register · Congress.gov
Text extraction
Output pages
⚲
Market Knowledge Graph
Interactive force-directed network across all 8 verticals. Nodes coloured by type: indications, drugs, approvals, sponsors, grants, policy acts, and more. Filter by node type, hover for confidence and source metadata. Tier 3 inferred edges shown as dashed links.
Open KG →
▲
Market Intelligence Signals
Disruption risk and shortage signals for 190 drug × indication pairs, grounded in observable KG data: FDA shortage flags, manufacturing recalls, and degree surges not visible in analyst consensus. Approval rank is a relative ordering tool only — labels are in-sample. Revenue index is directional; CMS data carries a 2yr lag. Expand any row for per-feature contribution bars and raw feature values.
Open Signals →
Weekly pipeline
Collect
06:00 Fetch 8 verticals
→
Analyse
08:15 GLM-5 Tier 2 extract
09:00 KG write
09:30 Centrality
09:45 Lead-lag
10:00 GLM-5 classify
10:30 Feature matrix
10:45 sklearn models
→
Deploy
11:00 Vercel deploy

Runs every Sunday 06:00–11:00 UK. Staggered before Thread 2 (11:45 UK) to avoid concurrent LLM calls. Single-writer KG with atomic file writes throughout.

Data coverage and signal limitations

This platform uses free public data sources only. Manufacturing, distribution, and sales verticals have structural gaps — no drug volume or revenue data is available from public sources at the resolution required for commercial market sizing. CMS Part D spending data has a ~2-year publication lag and covers Medicare-reimbursed spend only. All signal outputs are directional indicators, not forecasts. This platform is a research initiative and does not substitute for commercial market intelligence services.

ScienceClaw · HitchhikersAI · raminderpal@hitchhikersai.org · hitchhikersai.org